UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.668

Sortiert nach

Ole e 1, Ole e 7, and Ole e 9: Identifying distinct clinical subsets of olive tree–allergic patients

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.629-631.e3

2016

Link zum Volltext

Verfügbarkeit prüfen

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB120-AB120

2021

Link zum Volltext

Verfügbarkeit prüfen

Patterns of sensitization to inhalant allergens, Ole e 1 and Ole e 7 in children and adolescents born in the same area with different origin

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB129

2020

Link zum Volltext

Verfügbarkeit prüfen

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB97-AB97

2021

Link zum Volltext

Verfügbarkeit prüfen

Crystal structure of Pla l 1 reveals both structural similarity and allergenic divergence within the Ole e 1-like protein family

Journal of allergy and clinical immunology, 2017-07, Vol.140 (1), p.277-280

2017

Link zum Volltext

Verfügbarkeit prüfen

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB180-AB180

2022

Link zum Volltext

Verfügbarkeit prüfen

34367 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB106-AB106

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB10-AB10

2022

Link zum Volltext

Verfügbarkeit prüfen

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB143-AB143

2021

Link zum Volltext

Verfügbarkeit prüfen

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB142-AB142

2021

Link zum Volltext

Verfügbarkeit prüfen

Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB104

2020

Link zum Volltext

Verfügbarkeit prüfen

Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB72

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Journal of allergy and clinical immunology, 2021-02, Vol.147 (2), p.AB24-AB24

2021

Link zum Volltext

Verfügbarkeit prüfen

Ole Petter Ottersen: on health and wealth

The Lancet (British edition), 2014-02, Vol.383 (9917), p.593-593

Holmes, David

2014

Link zum Volltext

Verfügbarkeit prüfen

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy

Journal of allergy and clinical immunology, 2011-07, Vol.128 (1), p.178-184.e7

2011

Link zum Volltext

Verfügbarkeit prüfen

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB141-AB141

2020

Link zum Volltext

Verfügbarkeit prüfen

16292 Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB175-AB175

2020

Link zum Volltext

Verfügbarkeit prüfen

Consistent Reduction in HAE Attack Rate with Lanadelumab Regardless Of Baseline Attack Frequency: Interim Findings From the Phase 3 HELP Study Open Label Extension (OLE)

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB103

2020

Link zum Volltext

Verfügbarkeit prüfen

26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB120-AB120

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic targets for olive pollen allergy defined by gene markers modulated by Ole e 1-derived peptides

Molecular immunology, 2015-04, Vol.64 (2), p.252-261

2015

Link zum Volltext

Verfügbarkeit prüfen

A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates

Molecular immunology, 2012-02, Vol.50 (1-2), p.83-90

2012

Link zum Volltext

Verfügbarkeit prüfen

Development of a Dendrimeric Structure containing ole e 1 and CpG to Modulate an Allergic Response in an Experimental Model

Journal of allergy and clinical immunology, 2012-02, Vol.129 (2), p.AB131-AB131

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical efficacy and safety of brodalumab (KHK4827), an antiinterleukin-17-receptor a monoclonal antibody, in Japanese patients with moderate to severe plaque psoriasis: An open-label extension (OLE) study (4827-003 study)

Journal of the American Academy of Dermatology, 2015-05, Vol.72 (5), p.AB228-AB228

2015

Link zum Volltext

Verfügbarkeit prüfen

Identification, isolation, and characterization of Ole e 7, a new allergen of olive tree pollen

Journal of allergy and clinical immunology, 1999-10, Vol.104 (4), p.797-802

1999

Link zum Volltext

Verfügbarkeit prüfen

Analysis of IgE and IgG B-cell immunodominant regions of Ole e 1, the main allergen from olive pollen

Molecular immunology, 2006-02, Vol.43 (6), p.570-578

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.668

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical And Experimental Allergy

ThemaPharmacology & Pharmacy

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

KollektionJournals@Ovid Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.663)
Mit Volltextzugriff
(1.620)

Publikationsform

Sprache

Englisch
(1.656)
Japanisch
(252)
Norwegisch
(30)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(1.022)
Science & Technology
(1.022)
Humans
(789)
Male
(524)
Female
(488)
Biological And Medical Sciences
(383)
Neurosciences
(322)
Neurosciences & Neurology
(319)
Animals
(307)
Medical Sciences
(304)
Adult
(281)
Middle Aged
(227)
Aged
(163)
Immunology
(162)
Radiology, Nuclear Medicine & Medical Imaging
(154)
Neuroimaging
(151)
General & Internal Medicine
(141)
Medicine, General & Internal
(133)
Cardiovascular System & Cardiology
(128)
Cardiac & Cardiovascular Systems
(126)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Lancet
(290)
Neuroimage
(201)
Journal Of Allergy And Clinical Immunology
(130)
Journal Of The American Academy Of Dermatology
(84)
Molecular Immunology
(83)
The American Journal Of Cardiology
(77)
The American Heart Journal
(72)
Pain
(71)
Environmental Research
(64)
European Journal Of Pharmacology
(43)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Ole e 1, Ole e 7, and Ole e 9: Identifying distinct clinical subsets of olive tree–allergic patients

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE)

Patterns of sensitization to inhalant allergens, Ole e 1 and Ole e 7 in children and adolescents born in the same area with different origin

26313 Efficacy and safety of dupilumab for up to 1 year in a phase 3 open-label extension (OLE) trial (LIBERTY AD PED-OLE) in adolescents with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Crystal structure of Pla l 1 reveals both structural similarity and allergenic divergence within the Ole e 1-like protein family

34358 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years

34367 Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years

Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial

27424 Infections in adults with moderate-to-severe atopic dermatitis treated with dupilumab: long-term data from an open-label extension (OLE) study

27419 Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study

Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study

Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children

Long-term Impact of Lanadelumab on Patients with Hereditary Angioedema (HAE) Type 1/2: Patient Reported Outcome (PRO) Findings from the HELP Open-label Extension Study (OLE)

Ole Petter Ottersen: on health and wealth

Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy

15108 Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)

16292 Dupilumab treatment for up to 3 years demonstrates sustained efficacy in adult patients with moderate to severe atopic dermatitis: Results from LIBERTY AD Adult OLE

Consistent Reduction in HAE Attack Rate with Lanadelumab Regardless Of Baseline Attack Frequency: Interim Findings From the Phase 3 HELP Study Open Label Extension (OLE)

26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

Therapeutic targets for olive pollen allergy defined by gene markers modulated by Ole e 1-derived peptides

A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates

Development of a Dendrimeric Structure containing ole e 1 and CpG to Modulate an Allergic Response in an Experimental Model

Clinical efficacy and safety of brodalumab (KHK4827), an antiinterleukin-17-receptor a monoclonal antibody, in Japanese patients with moderate to severe plaque psoriasis: An open-label extension (OLE) study (4827-003 study)

Identification, isolation, and characterization of Ole e 7, a new allergen of olive tree pollen

Analysis of IgE and IgG B-cell immunodominant regions of Ole e 1, the main allergen from olive pollen

Aktive Filter

Suchergebnisse filtern